Stock Worth Mentioning Today: Is Selling Stock Like Celldex Therapeutics, Inc. After Such Decline Winning Strategy?

Stock Worth Mentioning Today: Is Selling Stock Like Celldex Therapeutics, Inc. After Such Decline Winning Strategy?

The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a huge mover today! About 1.49 million shares traded hands. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has risen 15.22% since March 8, 2016 and is uptrending. It has outperformed by 5.90% the S&P500.
The move comes after 7 months negative chart setup for the $407.38 million company. It was reported on Oct, 11 by We have $3.48 PT which if reached, will make NASDAQ:CLDX worth $48.89M less.

Analysts await Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report earnings on November, 3. They expect $-0.31 earnings per share, up 3.13% or $0.01 from last year’s $-0.32 per share. After $-0.32 actual earnings per share reported by Celldex Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -3.13% EPS growth.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Out of 11 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 6 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 55% are positive. Celldex Therapeutics has been the topic of 15 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Buy” rating given on Tuesday, March 8 by H.C. Wainwright. The stock has “Hold” rating given by Jefferies on Tuesday, August 9. The firm has “Market Perform” rating by Leerink Swann given on Monday, March 7. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Perform” rating given on Monday, March 7 by Oppenheimer. The rating was downgraded by Wedbush to “Neutral” on Monday, March 7. Cantor Fitzgerald maintained the stock with “Buy” rating in Friday, February 26 report. The firm earned “Buy” rating on Tuesday, August 11 by Brean Capital. The company was maintained on Tuesday, March 8 by Cowen & Co. The firm earned “Outperform” rating on Tuesday, August 11 by Oppenheimer. TH Capital maintained it with “Buy” rating and $39 target price in Tuesday, August 11 report.

According to Zacks Investment Research, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.”

More recent Celldex Therapeutics, Inc. (NASDAQ:CLDX) news were published by: which released: “Why Celldex Therapeutics, Inc. Jumped Higher Today” on October 04, 2016. Also published the news titled: “Why Celldex Therapeutics, Inc. Ran Higher Today” on September 27, 2016.‘s news article titled: “Why Celldex Therapeutics, Inc. Stock Sank 28.1% in August” with publication date: September 12, 2016 was also an interesting one.

CLDX Company Profile

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Firm is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Firm drug candidates are derived from a set of complementary technologies, which have the ability to utilize the human immune system and enable the creation of therapeutic agents. The Firm is using the technologies to develop targeted immunotherapeutics consist of protein molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). The Company’s Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. The Company’s Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment